The glucagon-like peptide 1 (GLP-1) agonist liraglutide has been reported to improve hepatic metabolic dysfunction and inflammation and reduce hepatic lipid build-up in patients with NAFLD [5, 6]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.